PPARG and type 2 diabetes mellitus: Rational drug design has been widely accomplished, to discover and optimize innovative leads for different molecular targets of type II diabetes including DPP-IV, α-glucosidase, peroxisome proliferator-activated receptor gamma (PPARγ), glycogen synthase kinase-3β (GSK-3β), glucokinase (GK), and others (9).